IDEAYA BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.71 USD | -1.92% |
|
-6.89% | +5.99% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 151.5 | 406.8 | 909.9 | 874.2 | 2,293 | 2,854 | - | - |
| Enterprise Value (EV) 1 | 151.5 | 406.8 | 663.1 | 501.1 | 1,661 | 1,998 | 2,189 | 2,854 |
| P/E ratio | -2.23 x | -10 x | -16.8 x | -12.8 x | -18.2 x | -16 x | -19.8 x | -17.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 20.8 x | 32.6 x | 17.2 x | 98.1 x | 236 x | 30.5 x | 32.7 x |
| EV / Revenue | - | 20.8 x | 23.7 x | 9.84 x | 71 x | 165 x | 23.4 x | 32.7 x |
| EV / EBITDA | - | - | -13.7 x | -8.3 x | -12.6 x | -10 x | -10.4 x | -15.3 x |
| EV / FCF | -3.84 x | 7.4 x | -11.4 x | -5.53 x | -14.1 x | -16.1 x | -11.2 x | -13.5 x |
| FCF Yield | -26% | 13.5% | -8.81% | -18.1% | -7.08% | -6.21% | -8.94% | -7.41% |
| Price to Book | 0.93 x | 1.75 x | 3.02 x | 2.15 x | 3.29 x | 2.63 x | 3.21 x | - |
| Nbr of stocks (in thousands) | 20,200 | 29,055 | 38,490 | 48,114 | 64,459 | 75,687 | - | - |
| Reference price 2 | 7.500 | 14.00 | 23.64 | 18.17 | 35.58 | 37.71 | 37.71 | 37.71 |
| Announcement Date | 3/24/20 | 3/23/21 | 3/15/22 | 3/7/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 19.54 | 27.94 | 50.93 | 23.38 | 12.12 | 93.57 | 87.32 |
| EBITDA 1 | - | - | -48.54 | -60.4 | -132 | -199.5 | -209.8 | -186.6 |
| EBIT 1 | -44.27 | -35.34 | -50.27 | -62.5 | -134.4 | -200.6 | -156.2 | -184.2 |
| Operating Margin | - | -180.9% | -179.91% | -122.72% | -574.85% | -1,655.74% | -166.91% | -210.98% |
| Earnings before Tax (EBT) 1 | -41.98 | -34.5 | -49.76 | -58.66 | -113 | -172.2 | -124.4 | -163.2 |
| Net income 1 | -41.98 | -34.5 | -49.76 | -58.66 | -113 | -175.6 | -143.4 | -170.2 |
| Net margin | - | -176.55% | -178.1% | -115.17% | -483.05% | -1,449.59% | -153.24% | -194.93% |
| EPS 2 | -3.360 | -1.400 | -1.410 | -1.420 | -1.960 | -2.358 | -1.900 | -2.114 |
| Free Cash Flow 1 | -39.42 | 54.97 | -58.42 | -90.62 | -117.6 | -124 | -195.7 | -211.5 |
| FCF margin | - | 281.35% | -209.09% | -177.92% | -502.85% | -1,023.37% | -209.12% | -242.21% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 3/23/21 | 3/15/22 | 3/7/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2.963 | 11.36 | 5.851 | 29.7 | 4.022 | 7.88 | 3.544 | 8.038 | 3.923 | - | 3.921 | 4.095 | 4.101 | - | - |
| EBITDA 1 | -17.92 | -13.76 | -21.99 | 1.229 | -25.89 | -25.69 | - | - | - | - | -51.66 | -54.07 | -56.67 | - | - |
| EBIT 1 | -18.37 | -14.22 | -22.5 | 0.66 | -26.44 | -26.28 | -32.71 | -33.53 | -41.92 | -51.02 | -48.17 | -49.99 | -51.46 | - | - |
| Operating Margin | -619.95% | -125.19% | -384.53% | 2.22% | -657.48% | -333.49% | -922.94% | -417.09% | -1,068.44% | - | -1,228.5% | -1,220.71% | -1,254.81% | - | - |
| Earnings before Tax (EBT) 1 | -18.21 | -14.01 | -22.06 | 1.615 | -24.2 | -23.64 | -27.93 | -27.44 | -33.96 | -39.57 | -42.41 | -44.09 | -46.09 | - | - |
| Net income 1 | -18.21 | -14.01 | -22.06 | 1.615 | -24.2 | -23.64 | -27.93 | -27.44 | -33.96 | -39.57 | -42.81 | -44.73 | -47.03 | - | - |
| Net margin | -614.65% | -123.36% | -376.96% | 5.44% | -601.72% | -300% | -787.98% | -341.38% | -865.54% | - | -1,091.75% | -1,092.29% | -1,146.9% | - | - |
| EPS 2 | -0.4700 | -0.3600 | -0.5700 | 0.0400 | -0.5000 | -0.4900 | -0.5000 | -0.4600 | -0.5200 | -0.5300 | -0.5652 | -0.5910 | -0.6181 | -0.7200 | -0.7400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/15/22 | 5/10/22 | 8/15/22 | 11/8/22 | 3/7/23 | 5/9/23 | 8/10/23 | 11/7/23 | 2/20/24 | 5/7/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 247 | 373 | 633 | 856 | 665 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -39.4 | 55 | -58.4 | -90.6 | -118 | -124 | -196 | -212 |
| ROE (net income / shareholders' equity) | -163% | -23.1% | -19.9% | -18% | -23.3% | -22.4% | 7.26% | -35.4% |
| ROA (Net income/ Total Assets) | -40.1% | -16.8% | -14.6% | -15.2% | -21.8% | -19.4% | 41.8% | - |
| Assets 1 | 104.8 | 205.6 | 339.8 | 384.7 | 518.6 | 906 | -343.2 | - |
| Book Value Per Share 2 | 8.030 | 8.020 | 7.820 | 8.430 | 10.80 | 14.30 | 11.70 | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.35 | 0.49 | 2.64 | 3.44 | 2.37 | 2.23 | 2.67 | 4 |
| Capex / Sales | - | 2.52% | 9.46% | 6.76% | 10.13% | 18.43% | 2.85% | 4.58% |
| Announcement Date | 3/24/20 | 3/23/21 | 3/15/22 | 3/7/23 | 2/20/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
37.71
USD
Average target price
52.82
USD
Spread / Average Target
+40.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.99% | 2.85B | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +44.93% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
- Stock Market
- Equities
- IDYA Stock
- Financials IDEAYA Biosciences, Inc.
